Combined inhibition of ALK and HDAC induces synergistic cytotoxicity in neuroblastoma cell lines

K Hagiwara, T Tokunaga, H Iida, H Nagai - Anticancer research, 2019 - ar.iiarjournals.org
Background/Aim: Neuroblastoma (NB) is the most common extracranial solid tumor in
childhood; treatments with greater effectiveness are required for NB, especially in advanced …

[HTML][HTML] Alectinib, an anaplastic lymphoma kinase inhibitor, abolishes ALK activity and growth in ALK-positive neuroblastoma cells

MW Alam, M Borenäs, DE Lind… - Frontiers in …, 2019 - frontiersin.org
Oncogenic receptor tyrosine kinases including anaplastic lymphoma kinase (ALK) are
implicated in numerous solid and hematologic cancers. ALK mutations are reported in an …

[HTML][HTML] Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis

Y Wang, L Wang, S Guan, W Cao, H Wang, Z Chen… - Scientific reports, 2016 - nature.com
ALK receptor tyrosine kinase has been shown to be a therapeutic target in neuroblastoma.
Germline ALK activating mutations are responsible for the majority of hereditary …

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684

C Schönherr, K Ruuth, Y Yamazaki… - Biochemical …, 2011 - portlandpress.com
Mutations in the kinase domain of ALK (anaplastic lymphoma kinase) have recently been
shown to be important for the progression of the childhood tumour neuroblastoma. In the …

[HTML][HTML] New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK

D Di Paolo, D Yang, F Pastorino, L Emionite, M Cilli… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Many different aberrations in the Anaplastic Lymphoma Kinase (ALK) were found to be
oncogenic drivers in several cancers including neuroblastoma (NB), therefore ALK is now …

[HTML][HTML] Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology

F Pastorino, M Capasso, C Brignole, VA Lasorsa… - Cancers, 2023 - mdpi.com
Simple Summary Approximately 50% of high-risk neuroblastomas (NB) relapse within two
years after the end of treatment. The prognosis for relapsed or refractory patients is poor …

The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic …

J Lu, S Guan, Y Zhao, Y Yu, SE Woodfield, H Zhang… - Cancer letters, 2017 - Elsevier
Activating germline mutations of anaplastic lymphoma kinase (ALK) occur in most cases of
hereditary neuroblastoma (NB) and the constitutively active kinase activity of ALK promotes …

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

J Guan, ER Tucker, H Wan, D Chand… - Disease models & …, 2016 - journals.biologists.com
The first-in-class inhibitor of ALK, c-MET and ROS1, crizotinib (Xalkori), has shown
remarkable clinical efficacy in treatment of ALK-positive non-small cell lung cancer …

[HTML][HTML] Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse

L Chen, A Humphreys, L Turnbull, A Bellini… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Abstract Anaplastic Lymphoma Kinase (ALK) is a transmembrane receptor kinase that
belongs to the insulin receptor superfamily and has previously been shown to play a role in …

[HTML][HTML] Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice

JT Siaw, H Wan, K Pfeifer, VM Rivera, J Guan… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor which has been implicated
in numerous solid and hematologic cancers. ALK mutations are reported in about 5-7% of …